Overview

Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate

Status:
Withdrawn
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This pilot phase II trial studies docetaxel and prednisone in treating patients with newly diagnosed stage I-II prostate cancer undergoing prostatectomy. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Biological therapies, such as prednisone, may stimulate the immune system in different ways and stop cancer cells from growing. Giving docetaxel and prednisone together may kill more tumor cells.
Phase:
Phase 2
Details
Lead Sponsor:
John P. Fruehauf
Collaborator:
Sanofi
Treatments:
Cortisone
Docetaxel
Prednisone